
    
      This is a randomized double-blind healthy control study and the implementation period is
      after Institutional Review Board (IRB) approval to December 31, 2022.

      Experimental group: 80 subjects who meet the criteria for the admission of Tourette's disease
      will be enrolled. They will consume the PS128 or placebo capsules every day, 2 capsules at a
      time, for 12 weeks. Healthy control group: 40 subjects of the same age as the experimental
      group will be included, without any intervention measures, only collect stool sample once.
    
  